Woman shares warning after tiny mark on cheek turns out to be cancer
Skin cancer on Christy Staats’s cheek measured just 0.025 inches.
Related Articles
Welcoming the Era of Gene Editing in Medicine | NEJM
Recent approvals of exa-cel for treatment of sickle cell disease and transfusion-dependent β-thalassemia mark the dawn of the era of gene editing in medicine. But…
Program Guide – ASCO Meeting Program Guide
1 – 20 out of 5893 Results for “2024 ASCO Annual Meeting” 5893 Results Select All Presenter: Jens Hoeppner, FAChirg, FACS, MD Presenter: Christian U.…
Tunneling nanotubes and tumor microtubes—Emerging data on their roles in intercellular communication and pathophysiology: Summary of an International FASEB Catalyst Conference October 2023
The FASEB Journal publishes multidisciplinary basic and translational research covering biology and biomedical sciences at every level of organization.
National Doctors’ Day – AMA Alliance
National Doctors’ Day in the United States is a holiday which is celebrated on March 30th each year. It is a holiday that honors physicians…
What to Know About Rising Cancer Rates in Young Women
Kate Middleton’s diagnosis mirrors a worrying trend.
Differential landscape of immune evasion in oncogenic RAS-driven primary and metastatic colorectal cancers
Lou and colleagues report a comprehensive analysis of 7,801 cases of colorectal cancer (CRC). They discovered significant differences in the tumor inflammatory microenvironment associated with…
Detailed Program | SRI 2024 Annual Meeting
President’s Distinguished Lecture I President’s New Investigator Plenary Supported by the Past Presidents’ Fund Moderators: Yoel Sadovsky, MD Kelle Moley, MD O-001: Maternal Extracellular Vesicle…
Tunneling nanotubes and tumor microtubes—Emerging data on their roles in intercellular communication and pathophysiology: Summary of an International FASEB Catalyst Conference October 2023
The FASEB Journal publishes multidisciplinary basic and translational research covering biology and biomedical sciences at every level of organization.
Tumor-Stroma Proportion Predicts Clinical Outcomes in Ovarian Cancer
A recent study found that tumor-stroma proportion was a reliable marker of chemoresistance, progression-free survival, and overall survival in high-grade serous ovarian cancer.
Research identifies predictor of outcomes, chemoresistance for ovarian cancer patients | MDLinx
Published February 28, 2024 | Originally published on MedicalXpress Breakin g News-and-Events Key points summarized by the MDLinx Team. Newly published research from an international…